Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Functional gene networks reveal distinct mechanisms segregating in migraine families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. No central action of CGRP antagonising drugs in the GTN mouse model of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Von Frey testing revisited - provision of an online algorithm for improved accuracy of 50% thresholds

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. ATP sensitive potassium (KATP) channel inhibition: A promising new drug target for migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Even Fjære
  • Ulrike L Aune
  • Kristin Røen
  • Alison H Keenan
  • Tao Ma
  • Kamil Borkowski
  • David M Kristensen
  • Guy W Novotny
  • Thomas Mandrup-Poulsen
  • Brian D Hudson
  • Graeme Milligan
  • Yannan Xi
  • John W Newman
  • Fawaz G Haj
  • Bjørn Liaset
  • Karsten Kristiansen
  • Lise Madsen
Vis graf over relationer

Chronic low grade inflammation is closely linked to obesity-associated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (±INDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6 β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HS+INDO-fed mice remained insulin-sensitive. However, mice fed HF/HS+INDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.

OriginalsprogEngelsk
TidsskriftThe journal of biological chemistry
Vol/bind289
Udgave nummer23
Sider (fra-til)16032-45
Antal sider14
ISSN0021-9258
DOI
StatusUdgivet - 2014

ID: 55228363